Ozmosi | Blonanserin Drug Profile

Product Description

Oral blonanserin (Lonasen) is an atypical antipsychotic agent indicated for use in patients with schizophrenia in Japan and Korea. It is effective in the treatment of patients with schizophrenia, providing short- and long-term efficacy against both the positive and negative symptoms of the disorder in several randomized and noncomparative trials. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/20030420/)

Mechanisms of Action: 5-HT2A Antagonist, D2 Antagonist, D3 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: India | Japan | Korea

Approved Indications: None

Known Adverse Events: None

Company: Dainippon Sumitomo Pharma America
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 4: Schizophrenia

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Latest Trial Update Date	Data Updated
ChiCTR2400094222	ChiCTR2400094222	N/A	Recruiting	Schizophrenia	2025-04-30
CTR20244947	CTR20244947	N/A	Completed	Schizophrenia	2025-03-12	2025-06-01	Patient Enrollment\|Primary Completion Date\|Start Date\|Study Completion Date\|Treatments\|Trial Status
CTR20243433	CTR20243433	N/A	Completed	Schizophrenia	2024-12-18	2025-06-01	Treatments
CTR20241926	CTR20241926	N/A	Completed	Schizophrenia	2024-08-27	2025-04-29	Patient Enrollment\|Primary Completion Date\|Start Date\|Study Completion Date\|Treatments\|Trial Status
CTR20233298	CTR20233298	N/A	Completed	Schizophrenia	2024-01-29	2025-04-29	Patient Enrollment\|Primary Completion Date\|Start Date\|Study Completion Date\|Treatments\|Trial Status
CTR20233299	CTR20233299	N/A	Completed	Schizophrenia	2024-01-16	2025-04-29	Patient Enrollment\|Primary Completion Date\|Start Date\|Study Completion Date\|Treatments\|Trial Status
CTR20230703	CTR20230703	N/A	Completed	Schizophrenia	2023-06-19	2025-04-29	Patient Enrollment\|Primary Completion Date\|Start Date\|Study Completion Date\|Treatments\|Trial Status
CTR20222736	CTR20222736	N/A	Completed	Schizophrenia	2022-12-07	2025-04-29
CTR20222272	CTR20222272	N/A	Completed	Schizophrenia	2022-10-21	2025-04-29	Patient Enrollment\|Primary Completion Date\|Start Date\|Study Completion Date
CTR20220686	CTR20220686	N/A	Completed	Schizophrenia	2022-09-02	2025-04-29	Patient Enrollment\|Primary Completion Date\|Start Date\|Study Completion Date\|Treatments\|Trial Status
CTR20221635	CTR20221635	N/A	Completed	Schizophrenia	2022-08-08	2025-04-29	Patient Enrollment\|Treatments
CTR20212449	CTR20212449	N/A	Completed	Schizophrenia	2021-12-17	2025-04-29	Patient Enrollment\|Treatments
CTR20212345	CTR20212345	N/A	Completed	Schizophrenia	2021-10-28	2025-04-29	Patient Enrollment\|Primary Completion Date\|Start Date\|Study Completion Date\|Treatments\|Trial Status
CTR20201741	CTR20201741	N/A	Completed	Schizophrenia	2020-12-09	2025-04-29	Treatments
CTR20201742	CTR20201742	N/A	Completed	Schizophrenia	2020-12-03	2025-04-29	Treatments
CTR20181415	CTR20181415	N/A	Completed	Schizophrenia	2019-02-01	2025-04-29	Patient Enrollment\|Treatments
JapicCTI-142423	JapicCTI-142423	P1	Completed	Schizophrenia	2014-07-31
JapicCTI-111725	JapicCTI-111725	P3	Unknown	Schizophrenia	2020-03-31
JapicCTI-111724	JapicCTI-111724	P3	Unknown	Schizophrenia	2019-03-19
JapicCTI-142688	JapicCTI-142688	P3	Completed	Schizophrenia	2018-12-31
NCT02287584	D4904020	P3	Completed	Schizophrenia	2018-12-01	2022-04-06
CTR20160821	CTR20160821	P3	Completed	Schizophrenia	2018-05-24	2025-04-29
JapicCTI-152765	JapicCTI-152765	P3	Completed	Schizophrenia	2017-07-31
NCT02335658	D4904040	P3	Completed	Schizophrenia	2017-05-01	2022-04-06
NCT03784222	DSPCLON-002	P4	Terminated	Schizophrenia	2022-11-22	2024-04-20

Recent News Events

Date	Type	Title
04/01/2024	PubMed	Severe behavioral and psychological symptoms of dementia successfully treated at home with a blonanserin transdermal patch: A case report.
03/20/2024	PubMed	Improvement of social functioning in patients with first-episode schizophrenia using blonanserin treatment: a prospective, multi-centre, single-arm clinical trial.
02/09/2024	PubMed	Successful Management of Terminal Delirium With Transdermal Blonanserin Patch in a Terminally Ill Cancer Patient.
05/20/2021	News Article	Transdermal Drug Delivery Market Report 2020-2030
05/15/2020	News Article	Transdermal Drug Delivery Industry Assessment 2018-2028 Featuring Profiles of 100 Companies along with 105 Collaborations - ResearchAndMarkets.com
05/15/2020	News Article	Worldwide Transdermal Drug Delivery Markets, Therapeutics, Technologies and Players - Forecast to 2028
08/01/2019	News Article	Transdermal Drug Delivery Markets, 2028

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

Blonanserin

Alternative Names: blonanserin, DSP-5423P, DSP-5423, DSP5423, DSP 5423 Clinical Status: Inactive Latest Update: 2024-04-19 Latest Update Note: Clinical Trial Update